Albert Seymour Sells 9,300 Shares of Homology Medicines Inc (NASDAQ:FIXX) Stock

Homology Medicines Inc (NASDAQ:FIXX) insider Albert Seymour sold 9,300 shares of Homology Medicines stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $16.23, for a total transaction of $150,939.00. Following the sale, the insider now owns 172,450 shares of the company’s stock, valued at $2,798,863.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Albert Seymour also recently made the following trade(s):

  • On Friday, November 29th, Albert Seymour sold 9,300 shares of Homology Medicines stock. The shares were sold at an average price of $16.06, for a total value of $149,358.00.
  • On Tuesday, October 1st, Albert Seymour sold 9,300 shares of Homology Medicines stock. The stock was sold at an average price of $17.39, for a total value of $161,727.00.

NASDAQ FIXX opened at $18.32 on Wednesday. The company has a market capitalization of $704.55 million, a PE ratio of -9.16 and a beta of 0.14. The company has a fifty day moving average of $13.72 and a 200 day moving average of $17.58. Homology Medicines Inc has a 1 year low of $11.05 and a 1 year high of $31.80.

Several analysts have weighed in on FIXX shares. Zacks Investment Research downgraded Homology Medicines from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Oppenheimer started coverage on Homology Medicines in a research note on Friday, November 1st. They issued a “market perform” rating for the company. ValuEngine downgraded Homology Medicines from a “buy” rating to a “hold” rating in a report on Monday, November 25th. Robert W. Baird started coverage on shares of Homology Medicines in a report on Monday, September 9th. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, HC Wainwright set a $36.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $31.40.

A number of institutional investors and hedge funds have recently made changes to their positions in FIXX. Aperio Group LLC purchased a new position in shares of Homology Medicines during the 2nd quarter valued at about $34,000. Bank of Montreal Can purchased a new stake in shares of Homology Medicines in the second quarter worth about $40,000. Cubist Systematic Strategies LLC acquired a new stake in Homology Medicines during the second quarter worth about $42,000. Marshall Wace LLP acquired a new stake in Homology Medicines during the first quarter worth about $74,000. Finally, Royal Bank of Canada grew its holdings in Homology Medicines by 300.0% during the second quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock worth $78,000 after acquiring an additional 3,000 shares during the period. 71.06% of the stock is currently owned by institutional investors.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Recommended Story: Net Income

Insider Buying and Selling by Quarter for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit